175 related articles for article (PubMed ID: 30572033)
1. Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model.
Suzuki K; Kim KS; Bae YH
J Control Release; 2019 Jan; 294():259-267. PubMed ID: 30572033
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice.
Bao X; Qian K; Yao P
J Nanobiotechnology; 2020 Apr; 18(1):67. PubMed ID: 32345323
[TBL] [Abstract][Full Text] [Related]
3. Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.
Hu M; Zhang Y; Xiang N; Zhong Y; Gong T; Zhang ZR; Fu Y
Pharm Res; 2016 Jun; 33(6):1318-26. PubMed ID: 26857900
[TBL] [Abstract][Full Text] [Related]
4. Sustained release of exendin-4 from tannic acid/Fe (III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes.
He Z; Hu Y; Gui Z; Zhou Y; Nie T; Zhu J; Liu Z; Chen K; Liu L; Leong KW; Cao P; Chen Y; Mao HQ
J Control Release; 2019 May; 301():119-128. PubMed ID: 30894322
[TBL] [Abstract][Full Text] [Related]
5. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1.
Li Y; Zheng X; Tang L; Xu W; Gong M
Peptides; 2011 Jun; 32(6):1303-12. PubMed ID: 21515323
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
[TBL] [Abstract][Full Text] [Related]
8. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
[TBL] [Abstract][Full Text] [Related]
9. Beneficial metabolic effects of dietary epigallocatechin gallate alone and in combination with exendin-4 in high fat diabetic mice.
Pathak NM; Millar PJB; Pathak V; Flatt PR; Gault VA
Mol Cell Endocrinol; 2018 Jan; 460():200-208. PubMed ID: 28754350
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
[TBL] [Abstract][Full Text] [Related]
11. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.
Wang Y; Xu B; Zhu L; Lou K; Chen Y; Zhao X; Wang Q; Xu L; Guo X; Ji L; Cui Y; Fang Y
Clin Drug Investig; 2017 Dec; 37(12):1107-1115. PubMed ID: 28932995
[TBL] [Abstract][Full Text] [Related]
13. Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.
Li H; Xu J; Fan X
J Pharmacol Sci; 2015 Feb; 127(2):170-80. PubMed ID: 25727954
[TBL] [Abstract][Full Text] [Related]
14. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
15. Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
Voronova V; Zhudenkov K; Penland RC; Boulton DW; Helmlinger G; Peskov K
Diabetes Obes Metab; 2018 Aug; 20(8):2034-2038. PubMed ID: 29663628
[TBL] [Abstract][Full Text] [Related]
16. Novel strategy for oral peptide delivery in incretin-based diabetes treatment.
Xu Y; Van Hul M; Suriano F; Préat V; Cani PD; Beloqui A
Gut; 2020 May; 69(5):911-919. PubMed ID: 31401561
[TBL] [Abstract][Full Text] [Related]
17. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.
Egan JM; Meneilly GS; Elahi D
Am J Physiol Endocrinol Metab; 2003 Jun; 284(6):E1072-9. PubMed ID: 12475750
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4 Loaded Nanoparticles with a Lipid Shell and Aqueous Core Containing Micelles for Enhanced Intestinal Absorption.
Chen C; Zhu X; Dou Y; Xu J; Zhang J; Fan T; Du J; Liu K; Deng Y; Zhao L; Huang Y
J Biomed Nanotechnol; 2015 May; 11(5):865-76. PubMed ID: 26349398
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats.
Celik-Tekeli M; Celebi N; Tekeli MY; Aktas Y
Eur J Pharm Sci; 2021 Mar; 158():105644. PubMed ID: 33197556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
